March 16, 2020 / 11:32 PM / 25 days ago

BRIEF-Immunic Says Cash And Cash Equivalents Expected To Fund Operations Into Q1 Of 2021

March 16 (Reuters) - Immunic Inc:

* IMMUNIC, INC. REPORTS YEAR END 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACHIEVEMENTS

* IMMUNIC INC - TOP-LINE DATA FROM PHASE 2 EMPHASIS TRIAL IN RELAPSING-REMITTING MULTIPLE SCLEROSIS EXPECTED IN Q3 2020

* IMMUNIC INC - CASH AND CASH EQUIVALENTS, AS OF DECEMBER 31, 2019, OF $29.4 MILLION, IS EXPECTED TO FUND COMPANY’S OPERATIONS INTO Q1 OF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below